228 related articles for article (PubMed ID: 23103871)
41. The biology of IGE and the basis of allergic disease.
Gould HJ; Sutton BJ; Beavil AJ; Beavil RL; McCloskey N; Coker HA; Fear D; Smurthwaite L
Annu Rev Immunol; 2003; 21():579-628. PubMed ID: 12500981
[TBL] [Abstract][Full Text] [Related]
42. An engineered disulfide bond reversibly traps the IgE-Fc3-4 in a closed, nonreceptor binding conformation.
Wurzburg BA; Kim B; Tarchevskaya SS; Eggel A; Vogel M; Jardetzky TS
J Biol Chem; 2012 Oct; 287(43):36251-7. PubMed ID: 22948141
[TBL] [Abstract][Full Text] [Related]
43. Interaction of a monoclonal IgE-specific antibody with cell-surface IgE-Fc epsilon RI: characterization of equilibrium binding and secretory response.
Posner RG; Paar JM; Licht A; Pecht I; Conrad DH; Hlavacek WS
Biochemistry; 2004 Sep; 43(35):11352-60. PubMed ID: 15366945
[TBL] [Abstract][Full Text] [Related]
44. FcepsilonRI-alpha siRNA inhibits the antigen-induced activation of mast cells.
Safaralizadeh R; Soheili ZS; Deezagi A; Pourpak Z; Samiei S; Moin M
Iran J Allergy Asthma Immunol; 2009 Dec; 8(4):177-83. PubMed ID: 20404387
[TBL] [Abstract][Full Text] [Related]
45. Membrane IgE binds and activates Fc epsilon RI in an antigen-independent manner.
Vangelista L; Soprana E; Cesco-Gaspere M; Mandiola P; Di Lullo G; Fucci RN; Codazzi F; Palini A; Paganelli G; Burrone OR; Siccardi AG
J Immunol; 2005 May; 174(9):5602-11. PubMed ID: 15843559
[TBL] [Abstract][Full Text] [Related]
46. Development of small molecules to target the IgE:FcεRI protein-protein interaction in allergies.
Smith LD; Leatherbarrow RJ; Spivey AC
Future Med Chem; 2013 Aug; 5(12):1423-35. PubMed ID: 23919552
[TBL] [Abstract][Full Text] [Related]
47. Structural basis of omalizumab therapy and omalizumab-mediated IgE exchange.
Pennington LF; Tarchevskaya S; Brigger D; Sathiyamoorthy K; Graham MT; Nadeau KC; Eggel A; Jardetzky TS
Nat Commun; 2016 May; 7():11610. PubMed ID: 27194387
[TBL] [Abstract][Full Text] [Related]
48. An anti-IgE monoclonal antibody that binds to IgE on CD23 but not on high-affinity IgE.Fc receptors.
Shiung YY; Chiang CY; Chen JB; Wu PC; Hung AF; Lu DC; Pan RL; Chang TW
Immunobiology; 2012 Jul; 217(7):676-83. PubMed ID: 22226669
[TBL] [Abstract][Full Text] [Related]
49. A novel IgE-neutralizing antibody for the treatment of severe uncontrolled asthma.
Cohen ES; Dobson CL; Käck H; Wang B; Sims DA; Lloyd CO; England E; Rees DG; Guo H; Karagiannis SN; O'Brien S; Persdotter S; Ekdahl H; Butler R; Keyes F; Oakley S; Carlsson M; Briend E; Wilkinson T; Anderson IK; Monk PD; von Wachenfeldt K; Eriksson PO; Gould HJ; Vaughan TJ; May RD
MAbs; 2014; 6(3):756-64. PubMed ID: 24583620
[TBL] [Abstract][Full Text] [Related]
50. Quantifying aggregation of IgE-FcepsilonRI by multivalent antigen.
Hlavacek WS; Perelson AS; Sulzer B; Bold J; Paar J; Gorman W; Posner RG
Biophys J; 1999 May; 76(5):2421-31. PubMed ID: 10233059
[TBL] [Abstract][Full Text] [Related]
51. Suppression of mast cell degranulation through a dual-targeting tandem IgE-IgG Fc domain biologic engineered to bind with high affinity to FcγRIIb.
Cemerski S; Chu SY; Moore GL; Muchhal US; Desjarlais JR; Szymkowski DE
Immunol Lett; 2012 Mar; 143(1):34-43. PubMed ID: 22305932
[TBL] [Abstract][Full Text] [Related]
52. Structure of the omalizumab Fab.
Jensen RK; Plum M; Tjerrild L; Jakob T; Spillner E; Andersen GR
Acta Crystallogr F Struct Biol Commun; 2015 Apr; 71(Pt 4):419-26. PubMed ID: 25849503
[TBL] [Abstract][Full Text] [Related]
53. Species Specificity on Interaction between IgE and FcεRI.
Li X; Wang N; Zhao Y; Zhang Y; Liu Z
Curr Pharm Biotechnol; 2019; 20(9):690-695. PubMed ID: 31258078
[TBL] [Abstract][Full Text] [Related]
54. Inhibition of allergen-specific IgE reactivity by a human Ig Fcgamma-Fcepsilon bifunctional fusion protein.
Zhang K; Kepley CL; Terada T; Zhu D; Perez H; Saxon A
J Allergy Clin Immunol; 2004 Aug; 114(2):321-7. PubMed ID: 15316510
[TBL] [Abstract][Full Text] [Related]
55. Regulation of allergy by Fc receptors.
Bruhns P; Frémont S; Daëron M
Curr Opin Immunol; 2005 Dec; 17(6):662-9. PubMed ID: 16214316
[TBL] [Abstract][Full Text] [Related]
56. p28, a novel IgE receptor-associated protein, is a sensor of receptor occupation by its ligand in mast cells.
Charles N; Monteiro RC; Benhamou M
J Biol Chem; 2004 Mar; 279(13):12312-8. PubMed ID: 14715661
[TBL] [Abstract][Full Text] [Related]
57. CD23 provides a noninflammatory pathway for IgE-allergen complexes.
Engeroff P; Caviezel F; Mueller D; Thoms F; Bachmann MF; Vogel M
J Allergy Clin Immunol; 2020 Jan; 145(1):301-311.e4. PubMed ID: 31437490
[TBL] [Abstract][Full Text] [Related]
58. The soluble isoform of human FcɛRI is an endogenous inhibitor of IgE-mediated mast cell responses.
Moñino-Romero S; Erkert L; Schmidthaler K; Diesner SC; Sallis BF; Pennington L; Jardetzky T; Oettgen HC; Bohle B; Fiebiger E; Szépfalusi Z
Allergy; 2019 Feb; 74(2):236-245. PubMed ID: 30030936
[TBL] [Abstract][Full Text] [Related]
59. Requirements for effective IgE cross-linking on mast cells and basophils.
Knol EF
Mol Nutr Food Res; 2006 Jul; 50(7):620-4. PubMed ID: 16764017
[TBL] [Abstract][Full Text] [Related]
60. Inhibition of antigen-induced mediator release from IgE-sensitized cells by a monoclonal anti-Fc epsilon RI alpha-chain receptor antibody: implications for the involvement of the membrane-proximal alpha-chain region in Fc epsilon RI-mediated cell activation.
Nechansky A; Robertson MW; Albrecht BA; Apgar JR; Kricek F
J Immunol; 2001 May; 166(10):5979-90. PubMed ID: 11342613
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
